Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 9Nausea 5Breast Neoplasms 4Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 45Carboplatin 33Bevacizumab 17liposomal doxorubicin 15Topotecan 12Taxes 10Gemcitabine 10Drug Therapy 6Cisplatin 6rucaparib 5mirvetuximab soravtansine 5Docetaxel 5Immunoglobulin G 4Doxorubicin 4Disulfides 4trebananib 3pembrolizumab 3olaparib 3Saline Solution 3Neoadjuvant Therapy 3Hyperthermic Intraperitoneal Chemotherapy 3Dexamethasone 3CP protocol 3niraparib 2cediranib 2Tamoxifen 2Specimen Handling 2Letrozole 2Glucose 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fallopian Tube Neoplasms × Aprepitant × Clear all
NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Sichuan Cancer Hospital and Research Institute

Phase 3 Completed
143 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡